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Multiple sclerosis (MS) is an immune mediated inflammatory disease that attacks myelinated axons 
in the central nervous system. Dalfampridine (4-aminopyridine) was approved by the Food and 
Drug Administration in January 2010 for treatment of MS. Our patient was a 34-year-old male with a 
history of MS, who was brought to the emergency department after being found unresponsive. His 
current medications were valacyclovir, temazepam, dalfampridine (4-AP) and a tysabri intravenous 
(IV) infusion. Fifteen minutes after arrival the patient seized. The seizures were refractory to 
benzodiazepines, barbiturates and phenytoin. The 4-AP level was 530ng/mL (25ng/mL and 49ng/
mL). The patient stopped seizing on hospital day 3 and was discharged 14 days later with normal 
mental status and neurologic exam. 4-AP is a potassium channel blocker that blocks the potassium 
ion current of repolarization following an action potential. The blockade of the potassium channel at 
the level of the membrane widens the action potential and enhances the release of acetylcholine, 
thus increasing post-synaptic action potentials. The treatment of patients with 4-AP overdose is 
supportive. Animal data suggest that patients with toxic levels of 4-AP may respond to phenytoin. 
Our case illustrates the highest recorded level of 4-AP in an overdose. Our patient appeared to be 
refractory to a combination of high doses of anticonvulsants and only improved with time. [West J 
Emerg Med. 2015;16(7):1177-1179.]
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INTRODUCTION
Multiple sclerosis (MS) is an immune-mediated 
inflammatory disease that attacks myelinated axons in the 
central nervous system. It is characterized by short-term 
episodes of neurologic deficits that usually resolve completely 
or almost completely. Patients with MS may suffer from pain 
due to spasticity, fatigue and progressive disability.1 There is 
currently no cure for the disease, but a plethora of treatments 
are available and are continuously being developed. 
One of the more novel medications on the market 
is dalfampridine, or 4-aminopyridine (4-AP). 4-AP 
was originally developed to be used as an avicide. The 
chemical was studied in mammals and was shown to 
cause hyperexcitability, hypersalivation, tremors, muscle 
incoordination, convulsions, cardiac or respiratory distress.2
4-AP acts as a voltage-gated potassium channel blocker 
that blocks the potassium ion current of repolarization in an 
axon following an action potential. Potassium efflux out of the 
axon is the ionic mechanism that results in repolarization of the 
axon. Repolarization must occur before the axon can generate 
another action potential. In MS, the myelin sheath is thinned 
and this results in either a weakened signal when the action 
potential reaches its destination or a complete block. This leads 
to weakness and fatigability of strength.3 The blockade of the 
potassium channel widens the action potential, and thus 4-AP 
increases the conduction of action potentials and this leads 
to increased strength.2 Due to the ability of 4-AP to reverse 
synaptic blockade it has been used as a treatment in many 
different neuromuscular disorders such as Alzheimer’s disease, 
botulism, Eaton Lambert syndrome and multiple sclerosis.4 In 
January 2010, 4-AP was approved by the FDA in the United 
States under the name dalfampridine to help patients with MS 
improve their gait and strength when walking.5
There are always new medications being developed 
for the treatment of MS, a disease with many potential 
comorbidities; among them, depression is the most notable. 
Western Journal of Emergency Medicine 1178 Volume XVI, NO. 7 : December 2015
A Massive Overdose of Dalfampridine Fil et al.
This occurs in part because MS is a chronic disease and 
also there are theories that it occurs because of frontal or 
subcortical white matter disease.6 Here we present a case of a 
4-AP overdose with the highest reported level in the literature.
CASE REPORT 
A 34-year-old male with a past medical history of MS 
was brought into the emergency department by Emergency 
Medical Services after being found unresponsive by his 
mother with three pill bottles at his side. The bottles were an 
empty bottle of valacyclovir, an empty bottle of temazepam 
and a bottle of dalfampridine still containing some pills. His 
mother gave the history that the patient was under multiple 
social stressors of late. Other than MS, the patient was 
diagnosed with insomnia and had no other pertinent past 
medical history. His current medications were valacyclovir, 
temazepam, dalfampridine (4-AP) and a tysabri IV infusion 
(all part of his MS treatment regimen). 
The initial vital signs were as follows: Blood pressure: 
155/82mmHg; Heart rate: 106/min; Respiratory rate: 24/min; 
Temperature: 97.4oF; O2 sat: 97% 2L NC. The bedside glucose 
was 144mg/dl. The patient appeared extremely tremulous, was 
awake, but not responding to questioning nor following simple 
commands. He responded to tactile stimulation by localizing to 
the pain. He did not appear to have any focal deficits. His pupils 
were 4 mm, equal and reactive and his mucous membranes 
were moist. His heart sounds were tachycardic, with no 
murmurs. The patient had clear breath sounds bilaterally and no 
retractions. The abdomen had normoactive bowel sounds. The 
skin was diaphoretic with piloerection. 
Intravenous access was established, labs were drawn and 
the patient was given two liters of normal saline. Soon after 
arrival, the patient lost consciousness, his oxygen saturation 
decreased to below 90% and he began to have a tonic-clonic 
seizure. The patient was administered boluses of lorazepam, 
to a total of 8 mg, without effect in seizure resolution. He 
was intubated and subsequently placed on a lorazepam and 
propofol infusion for sedation. He was loaded with one gram 
of phenytoin and 300mg phenobarbital and then placed on 
a phenobarbital infusion. Clinically the patient continued to 
have frequent, recurrent seizures.
The patients lab values on arrival were significant 
for a white blood cell count of 31.1×103/mcL, a sodium 
of 143mEq/L, potassium 3.1mEq/L, chloride 107mEq/L , 
bicarbonate of 24mEq/L, a blood urea nitrogen of 15mg/
dL and a creatinine of 1.2mg/dL. The anion gap was 12. 
The lactic acid was 3.4mg/dl. Total creatinine kinase was 
99 units/L. Liver function tests and coagulation studies 
were all within normal limits. Ethanol, acetaminophen 
and salicylate levels were all negative. A urine toxicology 
screen was positive for benzodiazepines. An arterial blood 
gas showed pH 7.22, pCO2 65, pO2 127 and HCO3 26.6 
(performed immediately after intubation). Computerized 
tomography of the brain and chest x-ray were both normal. 
The electrocardiogram showed a sinus rhythm at 88 beats 
per minute with normal QRS and QT intervals. Drug levels 
were sent for 4-AP and valacyclovir. The 4-AP level resulted 
at 530ng/mL (therapeutic: 25 to 49ng/mL). The valacyclovir 
level was 7.5mcg/mL (therapeutic 2.0-4.0mcg/mL).
The patient was admitted to the intensive care unit (ICU) 
and while he was there he continued to have seizures. While 
in the ICU the patient had two electroencephalographs (EEGs) 
performed. The EEG on hospital day 2 showed epileptiform 
activity and the other EEG was performed on hospital day 7 
and was indicative of epileptiform encephalopathy.
The patient stopped seizing on hospital day 3. The patient 
was extubated on hospital day 12. He was discharged, with 
normal mental status and neurologic exam to an inpatient 
psychiatric facility.
DISCUSSION 
Due to the fact that 4-AP is not a commonly used 
medication, not much is known about how it acts at toxic 
levels in humans. Van Diemen et al. looked at the dosage and 
serum level related to efficacy and safety. During this study 
a maximum daily dose of 0.5mg/kg body weight was not 
surpassed in any patient. Patients in this study experienced 
dizziness, paresthesias and restlessness at levels approaching 
0.5mg/kg. No patient in the study had a seizure, as the level at 
which seizures usually occur is 0.8mg/kg body weight.7
4-AP acts as a potassium channel blocker that prolongs 
the action potential, thus increasing neuromuscular activity. 
It is theorized that the increase in neuromuscular activity is 
therapeutic at appropriate levels, but that the same mechanism 
causes adverse reactions at elevated levels.8 The adverse reactions 
are not only of the central nervous system, but also include injury 
to the cardiac and skeletal muscle. One study showed that 4-AP 
toxicity could result in permanent damage to the hippocampus 
and Papez circuit affecting memory and learning.9
The 4-AP level of our patient resulted at 530ng/mL. 
Until now, the highest documented 4-AP level published 
was 233.6ng/mL.10 In that case, the patient was treated with 
lorazepam boluses and the seizures subsided, as opposed to 
our patient who was refractory to treatment with multiple 
anti-convulsant medications. The valacyclovir level was 
also elevated and valacyclovir itself can be associated 
with neuropsychiatric symptoms. Seizures associated with 
valacyclovir are not well reported in the literature, and the few 
case reports on valacyclovir associated seizures are in patients 
with renal failure, which our patient did not have.11,12
The current treatment of 4-AP overdose is supportive. 
Animal data suggests that patients with 4-AP toxicity 
will respond to phenytoin. It is hypothesized that because 
phenytoin acts as a sodium channel blocker it will inhibit 
action potentials from continuing.9 A study by Yamaguchi et 
al.13 showed that treatment of mice with elevated levels of 
4-AP with gamma butyric acid (GABA) was comparable to 
other phenytoin-like therapies. Our patient did not respond to 
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treatment with phenytoin. This raises the question of whether 
or not a second phenytoin load should be used, or additional 
anti-convulsants that have a similar mechanism of action to 
phenytoin should be added. 
Using phenytoin to treat seizures secondary to 4-AP is 
an important concept because phenytoin is not usually part 
of the algorithm for the treatment of toxin-induced seizures. 
The recommendation for treating an undifferentiated toxin-
induced seizure is to use a benzodiazepine or barbiturate, then 
pyridoxine and finally propofol.14 Toxin-induced seizures 
differ from seizures from other causes because they usually 
occur due to a global lowering of the seizure threshold in 
previously normal neurons, whereas seizures due to epilepsy 
occur in a focal lesion of abnormal neurons. Phenytoin is 
effective for patients with idiopathic seizure disorders or 
with defined structural or electrical foci of seizure activity, 
as phenytoin prevents the propagation of seizures (include 
reference). There are many reports of phenytoin used in toxin-
induced seizures causing clinical detriment to the patient.14
This case illustrates the highest recorded level of 4-AP in 
an overdose. Optimal therapy for this overdose is unknown. 
Our patient appeared to be refractory to a combination of high 
dose intravenous benzodiazepines, phenytoin, propofol and 
phenobarbital and only improved with time.
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